GlassScriptPhysician profile
Andrew N Lee
NPI 1417162090
$3,187.54
in general payments reported to CMS, 2019-2025
35 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $222 · 2021: $14.29 · 2022: $172 · 2023: $167 · 2024: $1,080 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,256.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $428.48 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $200.81 | 2019-2025 | Dupixent |
| Amgen INC. | $136.80 | 2024-2025 | Tezspire |
| Genzyme Corporation | $106.56 | 2019-2025 | |
| Insmed, INC. | $101.95 | 2019-2025 | Brinsupri, Arikayce |
| Verona Pharma, INC. | $95.55 | 2025 | Ohtuvayre |
| Philips North America LLC | $87.34 | 2019-2024 | (Ak6) Vest Therapy |
| Takeda Pharmaceuticals U.S.A., INC. | $82.80 | 2024-2025 | Aralast |
| Lundbeck LLC | $67.27 | 2023-2024 | Abilify Asimtufii, Abilify Maintena |
| Harmony Biosciences LLC | $60.69 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $49.29 | 2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $42.80 | 2024-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $41.59 | 2019-2020 | |
| Viiv Healthcare Company | $37.39 | 2025 | Dovato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $36.43 | 2025 | |
| Pfizer INC. | $31.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $27.29 | 2019 | |
| Vapotherm INC | $25.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.94 | 2019 | |
| Ani Pharmaceuticals, INC. | $22.04 | 2025 | Purified Cortrophin Gel |
| Soleno Therapeutics, INC. | $21.93 | 2025 | Vykat Xr |
| Baxter Healthcare | $19.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.21 | 2020 | |
| Resmed Corp | $19.13 | 2024 | |
| Viatris Specialty LLC | $16.67 | 2025 | Yupelri |
| Mylan Specialty L.P. | $16.10 | 2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $15.64 | 2024 | |
| United Therapeutics Corporation | $14.92 | 2025 | Tyvaso |
| Inspire Medical Systems, INC. | $14.74 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $14.38 | 2024 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.21 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $13.55 | 2024 | Lumryz |
| Nabriva Therapeutics, Plc | $13.27 | 2022 | |
| Shire North American Group INC | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.